Etravirine (TMC125, Intelence)

Overview | News & Research

Click here for a summary of the essential details on etravirine (TMC125, Intelence) from Cal Cohen, M.D.

Overview

Prescribing Information for Etravirine (TMC125, Intelence) (PDF) (February 2013)
From Tibotec Therapeutics
HIV/AIDS Update -- New Etravirine Labeling: Severe Skin and Hypersensitivity Reactions (August 2009)
Important drug warning.
To read PDF, click here.
From Tibotec Therapeutics
Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
News Analysis: U.S. Approval of Etravirine (Intelence) (January 25, 2008)
An interview with Cal Cohen, M.D., M.S.
From TheBodyPRO.com
Project Inform Welcomes Approval and Pricing of Intelence, Calls for Further Research (January 23, 2008)
From Project Inform
Etravirine (TMC125, Intelence) Approved by U.S. FDA (January 19, 2008)
From U.S. Food and Drug Administration
Overview of New HIV Antiretroviral Agents (December 17, 2007)
Translating HIV research into practice.
From TheBodyPRO.com

News & Research

Intelence (Etravirine) Labeling Updates (March 1, 2013)
From U.S. Food and Drug Administration
Darunavir/Ritonavir and Etravirine as a Prevention Method Is Biologically Plausible (Summer 2012)
To read PDF, click here.
In Being Alive Newsletter, from Being Alive
Intelence Now for Kids Ages 6 and Older (May/June 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Intelence (Etravirine): Pediatric Dosing Recommendations and New Scored 25 mg Tablet for Pediatric Dosing (March 26, 2012)
From U.S. Food and Drug Administration
Etravirine 200-mg Formulation Available in UK (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Pretreatment Mutations Do Not Affect Etravirine or Efavirenz Response in SENSE (September 21, 2011)
From National AIDS Treatment Advocacy Project
Detection of Baseline Resistance and HIV RNA Suppression to Week 48 in the SENSE Trial: Etravirine Versus Efavirenz in Treatment-Naive Participants (September 21, 2011)
From National AIDS Treatment Advocacy Project
Randomized Switch From Suppressive PI to Etravirine Safe and Effective (September 21, 2011)
From National AIDS Treatment Advocacy Project
Switching to Once-Daily Etravirine a Safe and Effective Option for Individuals Taking Suppressive Protease Inhibitor Therapy (September 20, 2011)
From aidsmap.com
ICAAC HIV Poster Roundup #1: Clinically Relevant Findings (September 19, 2011)
In The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	CROI 2013: Women's Issues in HIV Research (Video)
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.